NCT01935115.

Study name	A prospective randomized double‐blinded control trial using ketamine or propofol anesthesia for electroconvulsive therapy: improving treatment‐resistant depression
Methods	Allocation: randomised Endpoint classification: safety/efficacy study Intervention model: parallel assignment Masking: double‐blind (participant, caregiver, investigator, outcomes assessor)
Participants	Inclusion criteria Fulfill the diagnostic criteria for major depression according to the Diagnostic and Statistical Manual of Mental Disorders (most recent edition) Failure to respond to at least 2 adequate drug therapies for the current depression episode MADRS score of 20 or above (moderate ‐ severe ASA physical status classification I to III Exclusion criteria Inability to obtain informed consent ASA physical status classification IV Complication by any serious physical diseases such as cardiovascular disease (including untreated HTN), respiratory disease, cerebrovascular disease, intracranial HTN (including glaucoma), or seizures Presence of foreign body (including pacemaker) Pregnancy Allergies to anaesthetics used in study includes: a) ketamine b) propofol c) eggs d) egg products e) soybeans f) soy products
Interventions	ketamine 0.75 mg/kg intravenously versus propofol 1 mg/kg
Outcomes	Primary outcome measures: The primary outcome is defined as the number of ECT treatments required to reach a 50% reduction in baseline MADRS (Montgomery‐Asberg Depression Scale) score. Time frame: after 8 treatments or completion of therapy for an expected average of 4 weeks
Starting date	September 2013
Contact information	mailto:J_Gamble%40yahoo.com?subject=NCT01935115, UofSKetamine‐01, Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
Notes	NCT01935115